8-Aryl- and alkyloxycaffeine analogues as inhibitors of monoamine oxidase

Eur J Med Chem. 2011 Aug;46(8):3474-85. doi: 10.1016/j.ejmech.2011.05.014. Epub 2011 May 12.

Abstract

Recently it was reported that a series of 8-benzyloxycaffeine analogues are potent reversible inhibitors of human monoamine oxidase (MAO) A and B. In an attempt to discover additional C8 oxy substituents of caffeine that lead to potent MAO inhibition, a series of related 8-aryl- and alkyloxycaffeine analogues were synthesized and their MAO-A and -B inhibition potencies were compared to those of the 8-benzyloxycaffeines. The results document that while the 8-substituted-oxycaffeine analogues inhibited both human MAO isoforms, they displayed a high degree of selectivity for MAO-B. 8-(3-Phenylpropoxy)caffeine, 8-(2-phenoxyethoxy)caffeine and 8-[(5-methylhexyl)oxy]caffeine were found to be the especially potent MAO-B inhibitors with IC(50) values ranging from 0.38 to 0.62 μM. These inhibitors are therefore 2.5-4.6 fold more potent MAO-B inhibitors than is 8-benzyloxycaffeine (IC(50) = 1.77 μM). It is also demonstrated that, analogous to 8-benzyloxycaffeine, halogen substitution on the phenyl ring of the C8 substituent significantly enhances MAO binding affinity. For example, the most potent MAO-B inhibitor of the present series is 8-[2-(4-bromophenoxy)ethoxy]caffeine with an IC(50) value of 0.166 μM. This study also reports possible binding orientations of selected oxy caffeines within the active site cavities of MAO-A and MAO-B.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Alkylation
  • Animals
  • Binding Sites
  • Caffeine / analogs & derivatives
  • Caffeine / chemical synthesis*
  • Caffeine / pharmacology
  • Halogens / chemistry
  • Humans
  • Inhibitory Concentration 50
  • Kinetics
  • Kynuramine / metabolism
  • Mice
  • Models, Molecular
  • Monoamine Oxidase / chemistry
  • Monoamine Oxidase / metabolism*
  • Monoamine Oxidase Inhibitors / chemical synthesis*
  • Monoamine Oxidase Inhibitors / pharmacology
  • Neurodegenerative Diseases / drug therapy
  • Neurodegenerative Diseases / physiopathology
  • Protein Binding / drug effects*
  • Psychotic Disorders / drug therapy
  • Psychotic Disorders / physiopathology
  • Psychotropic Drugs / chemical synthesis*
  • Psychotropic Drugs / pharmacology
  • Recombinant Proteins / chemistry
  • Recombinant Proteins / metabolism*
  • Structure-Activity Relationship

Substances

  • Halogens
  • Monoamine Oxidase Inhibitors
  • Psychotropic Drugs
  • Recombinant Proteins
  • Kynuramine
  • Caffeine
  • Monoamine Oxidase